Showing 7 posts of 7 posts found.


Amgen wins high-profile cholesterol drug patent case v Sanofi

March 17, 2016
Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent

A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …

Sanofi Regeneron

FDA and EMA approve heart drug Praluent

July 27, 2015
Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent

The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …

Pfizer image

Pfizer launches cardiovascular research competition

April 10, 2015
Research and Development, Sales and Marketing Amgen, Astellas, LDL, PCSK9, Pfizer, bococizumab, inhibitors

Pfizer is funding a new competitive grants programme to support research projects in the burgeoning, competitive area of cholesterol-lowering PCSK9 …

Sanofi image

Sanofi and Amgen cholesterol drugs shine

March 16, 2015
Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent

Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …

Sanofi image

Sanofi showcases alirocumab at AHA

November 20, 2014
Sales and Marketing Amgen, PCSK9, Regeneron, Sanofi, aha, alirocumab, evolocumab

Sanofi and Regeneron released a battery of new Phase III data on their PCSK9 inhibitor alirocumab this week, reinforcing the …

Amgen image

Amgen submits next gen cholesterol drug

August 29, 2014
Sales and Marketing Amgen, FDA, PCSK9, Regeneron, Sanofi, statins

Amgen has put itself in pole position in the race to market the next generation of injectable statins known as …

Amgen image

Success for Amgen’s ‘bad’ cholesterol injection

March 18, 2014
Research and Development, Sales and Marketing Amgen, LDL, PCSK9, evolocumab, hofh, tesla

An investigational PCSK9 Inhibitor from Amgen has reduced LDL-C (‘bad’ cholesterol) in patients suffering from a rare genetic disorder in …

Latest content